160 results
8-K
EX-99.1
VBIVQ
VBI Vaccines Inc
3 Apr 24
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
8:00am
assessment (n=5)
2 stable disease (SD) have been observed in the VBI-1901 arm to-date
40% (n=2/5) early disease control rate achieved
Control Study Arm … response assessment (n=6)
No tumor responses have been observed in the SoC arm
0% (n=0/6) disease control rate
All evaluable patients have experienced
8-K
EX-1.1
hvy0zdozrnyxd4k95un
6 Jul 23
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants
6:47pm
8-K
EX-10.1
he96gg
15 Sep 22
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
5:01pm